John Fesko Sells 339 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 339 shares of the business’s stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $187.95, for a total value of $63,715.05. Following the transaction, the insider directly owned 152,408 shares of the company’s stock, valued at $28,645,083.60. This trade represents a 0.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

John Fesko also recently made the following trade(s):

• On Thursday, August 14th, John Fesko sold 678 shares of Natera stock. The stock was sold at an average price of $155.46, for a total value of $105,401.88.
• On Monday, July 28th, John Fesko sold 1,710 shares of Natera stock. The stock was sold at an average price of $139.81, for a total value of $239,075.10.

Natera Stock Performance

Natera stock opened at $195.00 on Friday. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $196.63. The stock has a market capitalization of $26.76 billion, a P/E ratio of -102.09 and a beta of 1.74. The stock has a fifty day moving average of $170.70 and a 200-day moving average of $159.76.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same period last year, the firm posted ($0.30) EPS. Natera’s quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of NTRA. Bank of Jackson Hole Trust acquired a new position in shares of Natera during the 1st quarter valued at $29,000. TCTC Holdings LLC lifted its position in shares of Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 124 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in shares of Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 106 shares during the period. Hilltop National Bank acquired a new position in shares of Natera during the 2nd quarter valued at $33,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Natera during the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $200.00 target price on shares of Natera in a report on Tuesday, October 14th. Morgan Stanley reaffirmed an “overweight” rating and issued a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Barclays reissued an “overweight” rating and issued a $210.00 price target (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Finally, Evercore ISI raised Natera to a “strong-buy” rating and set a $170.00 price target for the company in a research note on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $197.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.